Helping You DECIDE What’s Right For Your Patients

The Largest Prospective Registry on Plaque Analysis in Coronary Artery Disease

The DECIDE Registry is a landmark prospective study of ~20,000 patients at over 30 centers across the United States. DECIDE demonstrates how Heartflow Plaque Analysis with Plaque Staging* empowers physicians with clinical insights that lead to real-world impact. This is the next step in preventive CAD management, where diagnostic precision drives confident treatment planning.

gettyimages 2219968824 2
What if 50% of your CCTA patients could benefit from an adjustment to their treatment plan?
Traditional risk factors, such as age, family history, smoking, or hypertension, are useful for predicting CAD in populations but fall short at the individual level.1,2 While CCTA alone is capable of visualizing plaque, conventional interpretation1-3 doesn’t provide plaque quantity by type, which is proven to be a more accurate predictor of cardiac events.3 Plaque Analysis identifies and quantifies all plaque types, providing you with personalized data and Plaque Staging* insights to determine which 50% of your patients require changes to their treatment plans.4

The DECIDE Registry demonstrates it.
gettyimages 1403523137

Heartflow Plaque Staging

How Insights Transform Into Action

Highly validated Heartflow Plaque Staging* translates total plaque volume to inform actionable treatment plans, simplifying decision-making and personalizing preventive treatment based on patient risk.5,6
Learn More About Plaque Staging*

Why DECIDE Matters

Patients had their medical management changed when Plaque Analysis with Plaque Staging* was added compared to their management based on CCTA alone.
Patients with a calcified plaque score of 0 had a change in management compared to CCTA alone.
Suggested decrease in risk of cardiac events based on average LDL-C decrease of 18.7 mg/dL for those with change in management.¹
>50%
Patients had their medical management changed when Plaque Analysis with Plaque Staging* was added compared to their management based on CCTA alone.
third
Patients with a calcified plaque score of 0 had a change in management compared to CCTA alone.
~15%
Suggested decrease in risk of cardiac events based on average LDL-C decrease of 18.7 mg/dL for those with change in management.¹

Heartflow Is the Proven Choice for Plaque

With the DECIDE Registry, Heartflow continues to deliver high-quality evidence, proving again our commitment to transforming how CAD is managed — one insight, one patient, and one decision at a time.
Download DECIDE Data Sheet

Join the Movement Toward Smarter, Preventive Care

Whether you're looking to improve treatment plans, outcomes, or gain greater confidence in how you care for your patients, Heartflow Plaque Analysis is the new standard in preventive CAD management. DECIDE what’s right for your patients today.